Table 3

The effects on steatosis of exposure to specific antiretroviral medication in 184 HIV-HCV coinfected patients
Antiretrovirals n

Exposure to ARV

Adjusted OR (95% CI)

p

Cumulative exposure duration (per 1year increase)

Adjusted OR (95% CI)

p
Nucleoside reverse transcriptase inhibitors 184 NE 1.05 (0.961.16) 0.30
zidovudine 144 1.11 (0.54-2.30) 0.77 1.03 (0.91-1.16) 0.65
lamivudine 161 1.10 (0.44-2.77) 0.82 1.01 (0.88-1.17) 0.84
stavudine 114 0.96 (0.51-1.78) 0.88 1.05 (0.90-1.24) 0.54
didanosine 105 1.20 (0.66-2.18) 0.57 1.04 (0.85-1.27) 0.70
zalcitabine 22 1.68 (0.60-4.72) 0.33 1.50 (0.68-3.34) 0.31
tenofovir 24 0.87 (0.33-2.27) 0.78 1.19 (0.69-2.07) 0.53
abacavir 24 0.55 (0.22-1.39) 0.20 0.98 (0.69-1.41) 0.94
Protease inhibitors 126 1.15 (0.59-2.24) 0.67 1.06 (0.90-1.25) 0.50
ritonavir 55 0.90 (0.46-1.75) 0.75 0.96 (0.71-1.28) 0.76
indinavir 68 0.94 (0.51-1.74) 0.84 1.14 (0.87-1.47) 0.34
nelfinavir 47 0.96 (0.48-1.89) 0.91 1.12 (0.79-1.59) 0.54
saquinavir 31 0.91 (0.41-2.00) 0.81 0.72 (0.45-1.14) 0.16
lopinavir-ritonavir 17 0.55 (0.19-1.63) 0.28 0.86 (0.54-1.37) 0.52
atazanavir 8 0.76 (0.17-3.43) 0.72 0.99 (0.35-2.81) 0.98
Non-nucleoside reverse transcriptase inhibitors 79 0.93 (0.50-1.74) 0.81 1.17 (0.88-1.55) 0.27
efavirenz 51 1.34 (0.67-2.69) 0.40 1.19 (0.88-1.63) 0.26
nevirapine 44 0.67 (0.33-1.35) 0.26 1.24 (0.77-2.00) 0.36

Adjusted for period of liver biopsy.

Abbreviations: OR, odds ratio; CI, confidence intervals; NE, not estimable.

Martinez et al.

Martinez et al. BMC Research Notes 2012 5:180   doi:10.1186/1756-0500-5-180

Open Data